Fig. 5.

CLR01 decreases transthyretin (TTR) burden and associated toxicity in dorsal root ganglia (DRG) of hTTR V30M/HSF mice. (A) Representative immunohistochemistry analysis of TTR, binding immunoglobulin protein (BiP), Fas, and 3-nitrotyrosine in DRG of mice treated with CLR01 (right panels; n = 14) and age-matched controls (left panels; n = 12); 20× magnification. Bar graph: quantification of immunohistochemical images is presented as percentage of occupied area ± SD (**p < 0.01; ***p < 0.005). (B) Representative anti-BiP and anti-TTR Western blots of DRG from CLR01- and vehicle-treated mice. Bar graph: normalized BiP/GAPDH and TTR/GAPDH density quantifications ± SD (**p < 0.01)